AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano TransMed Article
PDF (2.6 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Nomograms for predicting overall survival and cancer-specific survival of patients with stage Ⅳ renal cell carcinoma: A SEER population-based study

Yongfei Tang, Jingping Yuan†( ), Yabing Huang, Honglin Yan, Lin Liu, Na Zhan, Huihua He
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China

† Present address: Department of Pathology, Renmin Hospital of Wuhan University, 99 Ziyang Road, Wuchang District, Wuhan 430060, Hubei Province, China

Show Author Information

Abstract

Background

The purpose of this study was to explore independent favorable prognostic factors for predicting 1-, 3-, and 5-year overall survival (OS) and cancer-specific survival (CSS) in patients with stage Ⅳ cell renal cell carcinoma (RCC) by constructing nomograms.

Methods

A total of 2636 patients diagnosed with stage Ⅳ RCC from 2010 to 2015 were enrolled in the surveillance, epidemiology, and end results database. Multivariate Cox hazard regression and competing risk analysis were used for searching prognosis factors in the cohort. The nomograms were constructed for predicting 1-, 3-, and 5-year of OS and CSS. Concordance index (C-index) and the calibration curves were used to evaluate the discrimination and accuracy of the nomograms.

Results

Age, nephrectomy, histology, N stage, and brain/liver/lung metastasis were identified as independent favorable prognostic factors in OS and CSS via univariate and multivariate analyses. Other variables were further selected by clinical practice and net reclassification improvement (NRI). Finally, age, nephrectomy, histology, grade, tumor size, T stage, N stage, and bone/brain/liver/lung metastasis were chosen to construct nomograms. The C-index of the OS and CSS in nomograms were 0.697 (95% confidence interval (CI), 0.683–0.711) and 0.655 (95% CI, 0.639–0.671), respectively. The calibration curves revealed high consistency between the nomograms prediction and actual observation.

Conclusions

The nomograms may help clinicians to conveniently predict the survival of RCC patients with stage Ⅳ and provide guidance in choosing the suitable management.

Keywords

surveillanceprognosisnomogramoverall survivalstage Ⅳ renal cell carcinomacancer-specific survivalepidemiology and end results (SEER)

References

[1]

Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30.
Crossref Google Scholar
[2]

Choueiri, T. K.; Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 2017, 376, 354–366.
Crossref Google Scholar
[3]

Hock, L. M.; Lynch, J.; Balaji, K. C. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: An analysis of surveillance, epidemiology, and end results program data. J. Urol. 2002, 167, 57–60.
Crossref Google Scholar
[4]

Guo, S. J.; Yao, K.; He, X. B.; Wu, S. L.; Ye, Y. L.; Chen, J. X.; Wu, C. L. Prognostic significance of laterality in renal cell carcinoma: A population-based study from the surveillance, epidemiology, and end results (SEER) database. Cancer Med. 2019, 8, 5629–5637.
Crossref Google Scholar
[5]

Cohen, H. T.; McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 2005, 353, 2477–2490.
Crossref Google Scholar
[6]

Patel, H. D.; Gupta, M.; Joice, G. A.; Srivastava, A.; Alam, R.; Allaf, M. E.; Pierorazio, P. M. Clinical stage migration and survival for renal cell carcinoma in the United States. Eur. Urol. Oncol. 2019, 2, 343–348.
Crossref Google Scholar
[7]

Posadas, E. M.; Limvorasak, S.; Figlin, R. A. Targeted therapies for renal cell carcinoma. Nat. Rev. Nephrol. 2017, 13, 496–511.
Crossref Google Scholar
[8]

Sun, M.; Shariat, S. F.; Cheng, C.; Ficarra, V.; Murai, M.; Oudard, S.; Pantuck, A. J.; Zigeuner, R.; Karakiewicz, P. I. Prognostic factors and predictive models in renal cell carcinoma: A contemporary review. Eur. Urol. 2011, 60, 644–661.
Crossref Google Scholar
[9]

Négrier, S.; Escudier, B.; Gomez, F.; Douillard, J. Y.; Ravaud, A.; Chevreau, C.; Buclon, M.; Pérol, D.; Lasset, C. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Français d'Immunothérapie. Ann. Oncol. 2002, 13, 1460–1468.
Crossref Google Scholar
[10]

Chandrasekar, T.; Klaassen, Z.; Goldberg, H.; Kulkarni, G. S.; Hamilton, R. J.; Fleshner, N. E. Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. Urol. Oncol. : Semin. Orig. Invest. 2017, 35, 661.e7–661.e14.
Crossref Google Scholar
[11]

Angulo, J. C.; Manini, C.; López, J. I.; Pueyo, A.; Colás, B.; Ropero, S. The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments. Cancers 2021, 13, 2071.
Crossref Google Scholar
[12]

Li, N.; Zhang, H. Y.; Hu, K. Y.; Chu, J. F. A novel long non-coding RNA-based prognostic signature for renal cell carcinoma patients with stage Ⅳ and histological grade G4. Bioengineered 2021, 12, 6275–6285.
Crossref Google Scholar
[13]

Balachandran, V. P.; Gonen, M.; Smith, J. J.; DeMatteo, R. P. Nomograms in oncology: More than meets the eye. Lancet Oncol. 2015, 16, e173–e180.
Crossref Google Scholar
[14]

Camp, R. L.; Dolled-Filhart, M.; Rimm, D. L. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004, 10, 7252–7259.
Crossref Google Scholar
[15]

Pencina, M. J.; D'Agostino, R. B.; Steyerberg, E. W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat. Med. 2011, 30, 11–21.
Crossref Google Scholar
[16]

Harrell, F. E. Jr.; Lee, K. L.; Mark, D. B. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15, 361–387.
Crossref Google Scholar
[17]

Aron, M.; Nguyen, M. M.; Stein, R. J.; Gill, I. S. Impact of gender in renal cell carcinoma: An analysis of the SEER database. Eur. Urol. 2008, 54, 133–142.
Crossref Google Scholar
[18]

Verhoest, G.; Veillard, D.; Guillé, F.; Taille, A. D. L.; Salomon, L.; Abbou, C. C.; Valéri, A.; Lechevallier, E.; Descotes, J. L.; Lang, H. et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur. Urol. 2007, 51, 1298–1305.
Crossref Google Scholar
[19]

Taccoen, X.; Valeri, A.; Descotes, J. L.; Morin, V.; Stindel, E.; Doucet, L.; Joulin, V.; Bocqueraz, F.; Coulange, C.; Rambeaud, J. J. et al. Renal cell carcinoma in adults 40 years old or less: Young age is an independent prognostic factor for cancer-specific survival. Eur. Urol. 2007, 51, 980–987.
Crossref Google Scholar
[20]

Ljungberg, B.; Bensalah, K.; Canfield, S.; Dabestani, S.; Hofmann, F.; Hora, M.; Kuczyk, M. A.; Lam, T.; Marconi, L.; Merseburger, A. S. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 2015, 67, 913–924.
Crossref Google Scholar
[21]

Motzer, R. J.; Escudier, B.; Mcdermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015, 373, 1803–1813.
Crossref Google Scholar
[22]

Fernandes, D. S.; Lopes, J. M. Pathology, therapy, and prognosis of papillary renal carcinoma. Future Oncol. 2015, 11, 121–132.
Crossref Google Scholar
[23]

Deng, J.; Li, L.; Xia, H. M.; Guo, J.; Wu, X.; Yang, X. R.; Hong, Y. Y.; Chen, Q. K.; Hu, J. P. A comparison of the prognosis of papillary and clear cell renal cell carcinoma: Evidence from a meta-analysis. Medicine 2019, 98, e16309.
Crossref Google Scholar
[24]

Wright, J. L.; Risk, M. C.; Hotaling, J.; Lin, D. W. Effect of collecting duct histology on renal cell cancer outcome. J. Urol. 2009, 182, 2595–260.
Crossref Google Scholar
[25]

Lebacle, C.; Pooli, A.; Bessede, T.; Irani, J.; Pantuck, A. J.; Drakaki, A. Epidemiology, biology, and treatment of sarcomatoid RCC: Current state of the art. World J. Urol. 2019, 37, 115–123.
Crossref Google Scholar
[26]

Bianchi, M.; Sun, M.; Jeldres, C.; Shariat, S. F.; Trinh, Q. D.; Briganti, A.; Tian, Z.; Schmitges, J.; Graefen, M.; Perrotte, P. et al. Distribution of metastatic sites in renal cell carcinoma: A population-based analysis. Ann. Oncol. 2012, 23, 973–980.
Crossref Google Scholar
[27]

Bhindi, B.; Wallis, C. J. D.; Boorjian, S. A.; Thompson, R. H.; Farrell, A.; Kim, S. P.; Karam, J. A.; Capitanio, U.; Golijanin, D.; Leibovich, B. C. et al. The role of lymph node dissection in the management of renal cell carcinoma: A systematic review and meta-analysis. BJU Int. 2018, 121, 684–698.
Crossref Google Scholar
[28]

Sun, M.; Lughezzani, G.; Jeldres, C.; Isbarn, H.; Shariat, S. F.; Arjane, P.; Widmer, H.; Pharand, D.; Latour, M.; Perrotte, P. et al. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. Eur. Urol. 2009, 56, 775–781.
Crossref Google Scholar
[29]

Delahunt, B.; Cheville, J. C.; Martignoni, G.; Humphrey, P. A.; Magi-Galluzzi, C.; Mckenney, J.; Egevad, L.; Algaba, F.; Moch, H.; Grignon, D. J. et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am. J. Surg. Pathol. 2013, 37, 1490–1504.
Crossref Google Scholar
[30]

Delahunt, B.; Eble, J. N. History of the development of the classification of renal cell neoplasia. Clin. Lab. Med. 2005, 25, 231–246.
Crossref Google Scholar
[31]

Karakiewicz, P. I.; Briganti, A.; Chun, F. K. H.; Trinh, Q. D.; Perrotte, P.; Ficarra, V.; Cindolo, L.; De La taille, A.; Tostain, J.; Mulders, P. F. A. et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol. 2007, 25, 1316–1322.
Crossref Google Scholar
[32]

Zhang, G. H.; Wu, Y.; Zhang, J. S.; Fang, Z. Q.; Liu, Z. X.; Xu, Z. H.; Fan, Y. D. Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma. OncoTargets Ther. 2018, 11, 5535–5544.
Crossref Google Scholar
Nano TransMed
Volume 2 Issue 1,
March 2023
Article number: e9130014
DOI: 10.26599/NTM.2023.9130014
Cite this article:
Tang Y, Yuan J, Huang Y, et al. Nomograms for predicting overall survival and cancer-specific survival of patients with stage Ⅳ renal cell carcinoma: A SEER population-based study. Nano TransMed, 2023, 2(1): e9130014. https://doi.org/10.26599/NTM.2023.9130014

793

Views

93

Downloads

0

Crossref

Altmetrics
Received: 27 February 2023
Revised: 22 March 2023
Accepted: 23 March 2023
Published: 30 March 2023
© The Author(s) 2023. Nano TransMed published by Tsinghua University Press.

The articles published in this open access journal are distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Return